Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2041

Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.

Patents
2,000

Quick answer

2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10941159

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10941135

    Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10941433

    Neurotransmitter transport in probiotics

    Regents of the University of Minnesota · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10942183

    Methods of detecting progesterone receptor and of detecting an expression level

    Regents of the University of Minnesota · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10941248

    Methods for preparing functionalized polymers from polymer alcohols

    Nektar Therapeutics · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10941200

    TREM2 cleavage modulators and uses thereof

    Ludwig-Maximilians-Universitat Munchen · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10940168

    Method of treating Bruch's membrane hypofunction disease

    Altregen Co., Ltd. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10940241

    Formation of stable cartilage

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10939673

    Method of using mouse having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10941184

    Cell-penetrating compstatin analogs and uses thereof

    Apellis Pharmaceuticals, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10940153

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10941210

    Anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10941187

    GLP-1, exendin-4, peptide analogs and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10940142

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10940109

    Multilayer polymeric matrix based medical devices

    The Regents of the University of Colorado · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10941175

    Pyrrolopyrimidine nucleosides and analogs thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10940160

    Biomarkers for predicting responsiveness to decitabine therapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10940208

    Nanoassembled complexes of nucleic acids, avidin and biotinylated compounds for use as drug carriers

    UVERA SRL · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10941095

    Hydroxyl compounds and compositions for cholesterol management and related uses

    Esperion Therapeutics, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10940133

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    Jazz Pharmaceuticals Ireland Limited · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10940141

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10941128

    Thymoquinone derivatives for treatment of cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10941392

    Purification of cystathionine beta-synthase

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10946080

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10947198

    Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents

    The Board of Regents for Oklahoma State University · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10946047

    Extracellular vesicles with enhanced potency

    United Therapeutics Corporation · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10947238

    Wee1 kinase inhibitors and methods of making and using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10945988

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10946009

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10946044

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10947277

    Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10947302

    Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them

    The Regents of the University of California · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10947312

    Human antibodies to GFRα3 and methods of making thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10947505

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10945962

    Controlled-release peptide compositions and uses thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10947033

    Reduction in stress cracking of films

    Aquestive Therapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10945972

    Particulate materials

    Nektar Therapeutics · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10945503

    Systems, devices and methods for styling hair

    MIRAKEL TECHNOLOGIES, INC. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10945964

    Microencapsulated chitosan, methods of making and methods for the use thereof

    PRIMEX EHF · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10945993

    Methods of recruiting SDF-producing macrophages

    MedRegen, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10946005

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10946107

    Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10947254

    Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10946065

    Methods of treating fungal infections

    United States of America as represented by the Secretary of the Air Force · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10945996

    Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis

    THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10946000

    Method for treating cancer with combination therapy

    RedHill Biopharma Ltd. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10946006

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10946007

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2041?

2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.